Search clinical trials for: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)

Total 132 results

NRG Oncology
National Cancer Institute (NCI)

Recruiting

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (DEBRA)

Stage I Breast Cancer

United States, Canada, Hong Kong
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Breast Neoplasms

China
Novartis Pharmaceuticals

Completed

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)

HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer

Canada
Institute of Cancer Research, United Kingdom

Recruiting

PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (POETIC-A)

Breast Cancer Female

United Kingdom
Shayna Showalter, MD

Active, not recruiting

Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (POWER)

Breast Cancer Female

United States
Azienda Ospedaliero-Universitaria Careggi
University of Florence

Recruiting

ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged ≥70 Years Early Stage Breast Cancer (EUROPA)

Breast Cancer

Italy
Institut Claudius Regaud

Completed

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer (MIRHO)

Breast Cancer

France
Institut Claudius Regaud

Completed

Pharmacology of Adjuvant Hormonotherapy in Breast Cancer (PHACS)

Hormono-depending Adjuvant Breast Cancer

France
Gruppo Italiano Mammella (GIM)

Unknown

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Breast Cancer

Italy
The Netherlands Cancer Institute

Terminated

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Breast Cancer

Netherlands
Centre Oscar Lambret

Unknown

Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

Breast Cancer

France
University of Michigan Rogel Cancer Center

Completed

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer (LOGRIBMET)

Obesity | Breast Cancer | Arthralgia

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Breast Cancer

China
European Organisation for Research and Treatment...
Breast International Group; Menarini Group

Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA)

Stage IIB Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Stage III Breast Cancer

Belgium, Italy, Ireland, France, Germany
UNC Lineberger Comprehensive Cancer Center

Recruiting

Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) (CAMERAN)

Quality of Life | Breast Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

Breast Cancer

United States
Ottawa Hospital Research Institute

Completed

Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) (REaCT-RETT)

Early-stage Breast Cancer

Canada
Veronica Morgan Jones

Recruiting

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Breast Cancer | Breast Carcinoma | HER2-negative Breast Cancer | Node-negative Breast Cancer

United States
Fudan University

Unknown

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer (LEANEX)

Breast Cancer

China
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)

Hormone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Australia, Puerto Rico, New Zealand, Ireland, Peru, United Kingdom
Tolmar Inc.

Recruiting

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA)

Breast Cancer

United States, Mexico, Brazil, Canada, Puerto Rico, Argentina
Tolmar Inc.

Enrolling by invitation

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Breast Cancer

United States, Puerto Rico
Sanofi

Active, not recruiting

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Breast Cancer Metastatic

Korea, Republic of, Belgium, Taiwan, China, France, United States, Argentina, Australia, Brazil, Canada, Czechia, Greece, Israel, Italy, Japan, Latvia, Mexico, Poland, Puerto Rico, Russian Federation, Spain, Turkey, Ukraine
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast Carcinoma

United States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Breast Cancer

United States
University of Alabama at Birmingham
Genentech, Inc.

Completed

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

Metastatic Breast Cancer

United States
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC

Breast Neoplasms

China
IRCCS Azienda Ospedaliera Universitaria San Martino...
Clinical Research Technology S.r.l.

Active, not recruiting

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (GIM10-CONSENT)

Breast Cancer

Italy
SOLTI Breast Cancer Research Group
Novartis

Completed

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)

Breast Cancer

Spain
Merus N.V.

Completed

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Breast Cancer Metastatic

United States, France, Belgium, Spain, United Kingdom, Netherlands, Portugal
Sun Yat-sen University

Active, not recruiting

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (MECCA)

Breast Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

Breast Cancer

United States
Xu fei
Sun Yat-sen University

Unknown

Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer (BETTER)

Breast Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (Pyrotinib)

Breast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive Tumor
Pfizer

Active, not recruiting

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Breast Cancer | Hormone Receptor Positive Tumor

United States
Centre Leon Berard

Recruiting

Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) (BFR-ESS)

Low Grade Endometrial Stromal Sarcoma

France
Brigham and Women's Hospital
Johns Hopkins University; National Institute on Aging (NIA); Rutgers University

Active, not recruiting

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

Breast Cancer

United States
Fuzhou General Hospital

Not yet recruiting

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Breast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive Tumor

China
Gruppo Italiano Mammella (GIM)

Unknown

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Breast Cancer

Italy
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
wang shusen

Recruiting

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Breast Cancer

China
UNICANCER
Pfizer

Active, not recruiting

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection (PADA-1)

Metastatic Breast Cancer

France
University of Michigan Rogel Cancer Center
Damon Runyon Cancer Research Foundation

Completed

Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients

Pain | Breast Cancer | Arthralgia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Stage 0 Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | HER2/Neu Negative | Postmenopausal

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Metastatic Breast Cancer

China
Institut Claudius Regaud

Completed

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not (OXYTAM)

Breast Cancer

France
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors (PREDIX LumA)

Early-Stage Breast Carcinoma | Hormone Receptor Positive Tumor

Sweden
QuantumLeap Healthcare Collaborative

Recruiting

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Ductal Carcinoma in Situ

United States
Tianjin Medical University Cancer Institute and...

Recruiting

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

HR Positive HER2 Negative Advanced Breast Cancer

China

Search clinical trials for: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations